Sacutan 49 mg+51 mg (Tablet)
Unit Price: ৳ 85.00 (1 x 10: ৳ 850.00)
Strip Price: ৳ 850.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Unimed unihealth pharmaceuticals ltd |
| Also available as |
Indications
- Reduce the risk of cardiovascular death
- Hospitalization for heart failure in patients with chronic heart failure
- Treatment of symptomatic heart failure in pediatric patients
- Administered in conjunction with other heart failure therapies
- In place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB
Pharmacology
- Contains neprilysin inhibitor, sacubitril
- Contains angiotensin receptor blocker, valsartan
- Inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657
- Blocks the angiotensin II type-1 (AT1 ) receptor via valsartan
- Affects cardiovascular and renal systems in heart failure patients
Dosage & Administration
- Recommended starting dose for adult heart failure: 49/51 mg orally twice daily
- Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily
- Recommended starting dose for pediatric heart failure: Refer to Table 1 for the recommended dose
- Adjust pediatric patient doses every 2 weeks, as tolerated by the patient
Interaction
- Dual Blockade of the Renin-Angiotensin-Aldosterone System
- Potassium-sparing Diuretics
- NSAIDs
- Lithium
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in patients with diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired Renal Function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients
- No dose adjustment required for patients with mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
Precautions & Warnings
- May cause angioedema
- Lowers blood pressure and may cause symptomatic hypotension
- Monitor serum creatinine
- Monitor serum potassium periodically
Use in Special Populations
- Safety and effectiveness in pediatric patients not established
- No relevant pharmacokinetic differences observed in elderly patients
- Starting dose recommendations for severe renal impairment
- No starting dose adjustment needed for mild or moderate renal impairment
- Starting dose recommendations for moderate hepatic impairment
- No starting dose adjustment needed for mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
Overdose Effects
- Limited data available with regard to overdosage
- Hypotension is the most likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis due to high protein binding
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children